183 related articles for article (PubMed ID: 11307810)
1. Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin.
Sheth SB; DiCicco RA; Hursting MJ; Montague T; Jorkasky DK
Thromb Haemost; 2001 Mar; 85(3):435-40. PubMed ID: 11307810
[TBL] [Abstract][Full Text] [Related]
2. Transitioning from argatroban to warfarin in heparin-induced thrombocytopenia: an analysis of outcomes in patients with elevated international normalized ratio (INR).
Bartholomew JR; Hursting MJ
J Thromb Thrombolysis; 2005 Jun; 19(3):183-8. PubMed ID: 16082605
[TBL] [Abstract][Full Text] [Related]
3. Use of the chromogenic factor X assay to predict the international normalized ratio in patients transitioning from argatroban to warfarin.
Arpino PA; Demirjian Z; Van Cott EM
Pharmacotherapy; 2005 Feb; 25(2):157-64. PubMed ID: 15767231
[TBL] [Abstract][Full Text] [Related]
4. Use of the chromogenic factor X assay in patients transitioning from argatroban to warfarin therapy.
Austin JH; Stearns CR; Winkler AM; Paciullo CA
Pharmacotherapy; 2012 Jun; 32(6):493-501. PubMed ID: 22511112
[TBL] [Abstract][Full Text] [Related]
5. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time.
Harder S; Graff J; Klinkhardt U; von Hentig N; Walenga JM; Watanabe H; Osakabe M; Breddin HK
Thromb Haemost; 2004 Jun; 91(6):1137-45. PubMed ID: 15175800
[TBL] [Abstract][Full Text] [Related]
6. Prolonged anticoagulation after discontinuation of argatroban and warfarin therapy in an obese patient with heparin-induced thrombocytopenia.
Shapiro NL; Durr EA; Krueger CD
Pharmacotherapy; 2006 Dec; 26(12):1806-10. PubMed ID: 17125442
[TBL] [Abstract][Full Text] [Related]
7. Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia.
Hursting MJ; Lewis BE; Macfarlane DE
Clin Appl Thromb Hemost; 2005 Jul; 11(3):279-87. PubMed ID: 16015413
[TBL] [Abstract][Full Text] [Related]
8. Effect of lepirudin on the international normalized ratio.
Stephens JL; Koerber JM; Mattson JC; Smythe MA
Ann Pharmacother; 2005 Jan; 39(1):28-31. PubMed ID: 15590880
[TBL] [Abstract][Full Text] [Related]
9. Minimal Prolongation of Prothrombin Time with Extended Exposure to Argatroban.
McAlister RK; Ito S
Pharmacotherapy; 2015 Jul; 35(7):e122-6. PubMed ID: 26147471
[TBL] [Abstract][Full Text] [Related]
10. Argatroban anticoagulation in critically ill patients.
Beiderlinden M; Treschan TA; Görlinger K; Peters J
Ann Pharmacother; 2007 May; 41(5):749-54. PubMed ID: 17440009
[TBL] [Abstract][Full Text] [Related]
11. [A study of the dosage of argatroban for anticoagulation effect in the patients undergoing high volume hemofiltration].
Wang Y; Chen XM; Sun XF; Xiang J
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2009 Apr; 21(4):240-2. PubMed ID: 19374795
[TBL] [Abstract][Full Text] [Related]
12. Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values.
Gosselin RC; Dager WE; King JH; Janatpour K; Mahackian K; Larkin EC; Owings JT
Am J Clin Pathol; 2004 Apr; 121(4):593-9. PubMed ID: 15080313
[TBL] [Abstract][Full Text] [Related]
13. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects.
Swan SK; St Peter JV; Lambrecht LJ; Hursting MJ
Pharmacotherapy; 2000 Jul; 20(7):756-70. PubMed ID: 10907966
[TBL] [Abstract][Full Text] [Related]
14. Effect of argatroban on the activated partial thromboplastin time: a comparison of 21 commercial reagents.
Francis JL; Hursting MJ
Blood Coagul Fibrinolysis; 2005 Jun; 16(4):251-7. PubMed ID: 15870544
[TBL] [Abstract][Full Text] [Related]
15. Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): a randomized, placebo-controlled safety study.
LaMonte MP; Nash ML; Wang DZ; Woolfenden AR; Schultz J; Hursting MJ; Brown PM;
Stroke; 2004 Jul; 35(7):1677-82. PubMed ID: 15155959
[TBL] [Abstract][Full Text] [Related]
16. The clinical significance of differences between point-of-care and laboratory INR methods in over-anticoagulated patients.
Lawrie AS; Hills J; Longair I; Green L; Gardiner C; Machin SJ; Cohen H
Thromb Res; 2012 Jul; 130(1):110-4. PubMed ID: 21937093
[TBL] [Abstract][Full Text] [Related]
17. Reduced argatroban doses after coronary artery bypass graft surgery.
Hoffman WD; Czyz Y; McCollum DA; Hursting MJ
Ann Pharmacother; 2008 Mar; 42(3):309-16. PubMed ID: 18303137
[TBL] [Abstract][Full Text] [Related]
18. Dosing options for decreasing the time to achieve therapeutic anticoagulation when reinitiating warfarin: a case series.
Schultz KT; Bungard TJ
Pharmacotherapy; 2011 Aug; 31(8):793-805. PubMed ID: 21923606
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia.
Kiser TH; Jung R; MacLaren R; Fish DN
Pharmacotherapy; 2005 Dec; 25(12):1736-45. PubMed ID: 16305293
[TBL] [Abstract][Full Text] [Related]
20. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy.
Reddy BV; Grossman EJ; Trevino SA; Hursting MJ; Murray PT
Ann Pharmacother; 2005 Oct; 39(10):1601-5. PubMed ID: 16131539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
